Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14575670 | 0.81 | MMP9 (0.43) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL3448327 | 0.80 | KMT2A (0.64) | MMP2MMP9KMT2ACA2CA1 | |
| SCHEMBL3448329 | 0.80 | KMT2A (0.64) | MMP2MMP9KMT2ACA2CA1 | |
| Hydrochloric Acid SCHEMBL23834278 | 0.79 | KMT2A (0.62) | MMP2MMP9KMT2ACA2CA1 | |
| SCHEMBL176825 | 0.79 | CA2 (0.47) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL176845 | 0.79 | CA2 (0.51) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL14575853 | 0.78 | CA2 (0.53) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL176771 | 0.78 | CA2 (0.56) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL177108 | 0.78 | L3MBTL1 (0.45) | CASRMMP2MMP9KMT2ACA2 | |
| SCHEMBL176798 | 0.78 | CA2 (0.50) | CASRMMP2MMP9KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | CASR 1/4885MMP2 3359/4885MMP9 3076/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885MMP2 4470/4885MMP9 4267/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | CASR 3/4885MMP2 1132/4885MMP9 1970/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885MMP2 4470/4885MMP9 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.